피부과용 일반의약품(OTC) 시장 보고서 : 동향, 예측 및 경쟁 분석(-2035년)

Dermatology OTC Medication Market

The future of the global dermatology otc medication market looks promising with opportunities in the hospital and drug store markets. The global dermatology otc medication market is expected to reach an estimated $29.4 million by 2035 from $20.3 million in 2027 with a CAGR of 3.3% from 2027 to 2035. The major drivers for this market are the increasing awareness of skin health, the rising demand for at-home treatments, and the growing focus on natural ingredients.

• Lucintel forecasts that, within the type category, external use is expected to witness higher growth over the forecast period due to increased demand for topical as opposed to oral dermatological treatments.
• Within the application category, drug store is expected to witness higher growth over the forecast period due to easier shopping and greater convenience offered by drugstores.
• In terms of regions, APAC is expected to witness the highest growth over the forecast period due to increasing rates of skin disorders and higher levels of self-medication.

Emerging Trends in Dermatology OTC Medication Market

The market for over-the-counter (OTC) dermatology products is expected to shift from symptoms management to prevention and proactive care by 2027. Consumers are expected to rely on pharmacy and digital sources for the assessment and purchase of self-care dermatology products. Our observations align with trends reported by other sources. When making a purchase decision, consumers consider a combination of factors, including the ingredients supported by clinical data, tolerance, and worth-while value.

• Sustainability: Several dermatology companies have announced plans to reformulate and develop new products with a focus on reducing environmental impact and improving sustainability by 2027. Several product innovations with reduced environmental impact are anticipated during the same time frame.
• Functional Products: Products developed to address multiple dermatological conditions (e.g., pigmentation, acne and/or anti-aging) are expected to gain popularity during the same time frame. Facial products containing physical sun screening with a minimum SPF of 30 are expected to remain on the market during this time frame. Use of certain ingredients (i.e., ceramides) in facial products to address daytime hydration and protect against environmental stress is anticipated.
• Digital Commerce: Search tools and virtual consultations help pharmacists recommend OTC medications based on symptoms. Subscription models provide a convenient way for customers to automatically repurchase medications. By 2025, expect medications to be easily purchased online, similar to other consumer products. Transparency will create opportunities for manufacturers to acquire new customers.
• Premiumization: In 2025, expect the introduction of a greater number of clinical and dermatologist-tested skincare products. Even with the higher demand and greater variety of clinical skincare products, generic skincare products will still be popular. The same will be true for 2% salicylic acid products. The acceptance of higher prices will be based on perceptions that skincare products that undergo clinical testing will have improved outcomes and lessen the risks associated with treatment.
• Regional Supply Chains: To reduce risk exposure and increase supply chain flexibility, manufacturers will produce products in more than one country. This will result in somewhat reliable product availability but greater costs and higher dual sourcing.

This paper outlined key trends which are expected to shape the skincare marketplace through 2027. Continuous improvements to products, packaging, and retail sourcing, in addition to an emphasis on sustainability will position companies to successfully and legally capture untapped skincare markets.

Recent Developments in the Dermatology OTC Medication Market

The OTC dermatology market is projected to grow during the 2025-2027 period as consumers [doctor] themselves for conditions including acne, eczema, and other skin conditions and damage caused by environmental factors. Traditional brand companies develop and introduce clinical evidence and formulations and educate consumers through digital means. Private label retailers introduce and distribute such products. The market is expected to grow further with more players redefining the market through regulation and dermatologist endorsement.

• Portfolio Consolidation: L'Oreal's June 2025 acquisition of Medik8, a clinical skincare brand with annual sales of approximately £100 million, signals L'Oreal's interest in the premium dermatologist-led skincare business. The acquisition is expected to spark further consolidation within the industry and increase competition for the pharmacy and specialty skincare retailer business.
• Evidence Led Acne Treatment: Product claims focusing on cosmetic endpoints are being replaced with clinical studies on the tolerance and efficacy of active ingredients. In 2025, the FDA disclosed the presence of benzene in several BP products, raising industry concerns on the stability of BP products and promoting the use of other actives. In the next 3-5 years, transparency in testing will influence the skincare industry and assist in regaining consumer trust.
• Self-care: Customers are looking to purchase less expensive medicines to treat conditions themselves rather than going to see a doctor. As reported by CVS Health, they have over 9,000 retail pharmacy locations. With this scale, CVS can further develop the over the counter dermatology product offerings. Enhancing shelf space and differentiating pharmacy products from one another will provide CVS a competitive edge.
• Integrated Digital Care: The integration of teledermatology increases the availability of diagnostics, treatment, and OTC products. With over 2 million members, Amazon's acquisition of One Medical increased the availability and access to teledermatology. Expect other Skin Care products to integrate therapeutic aids, adherence aids, and behavioral aids.
• Manufacturing: Raw ingredient supplier reliability improved traceability and planning of raw material supply. Perrigo increased their net sales by over $4 billion in 2024. Other consumer health product companies improved their raw material supply reliability. Until 2029, expect suppliers that improved raw material supply reliability to increase their market share of OTC products.

As the raw material supply reliability improved, so did product traceability and quality. This allowed manufacturers to differentiate products based on clinical evidence. The migration of product value coupled with improved supply reliability, increased regulatory oversight of the industry to enhance claims validation and remove false and/or unsubstantiated product claims. Overall, this benefits the industry and helps strengthens market trust.

Strategic Growth Opportunities in the Dermatology OTC Medication Market

The dermatology otc medication market is expected to expand as consumers increasingly self-treat medical conditions including acne, eczema, and skin infections and as pharmacies broaden their fulfilment services. Regulatory changes governing Rx-to-OTC switching, combined with industry efforts to educate the public regarding OTC ingredients and allowable product claims, will significantly affect this market between 2024 and 2026. In this regard, industry experts anticipate a shift from general-market products to more targeted products.

• Home Acne Care and Eczema Care: The market for over-the-counter acne and eczema treatments will benefit from the growing popularity of preventative skincare treatments. Barrier repair creams infused with active ingredients targeting acne, for example, could build brand loyalty. Acne affects an estimated 50 million people in the U.S. alone, according to the 2025 AAD report.
• Premium Dermo Cosmetics: Other markets which would likely benefit from preventative skincare treatments include acne-prone consumers of all ages. The public's interest in derma- and cosmetics will remain and create opportunities for manufacturers to raise prices.
• Digital Care: CVS Health expects positive revenue impact from recent launches of online consultations and prescription refills. As of February 2025, CVS Health owns and operates about 9,000 pharmacies in the U.S. The company expects that pharmacy digital paths will increase in the next few years, as customers will prefer getting treatment without physically visiting a pharmacy.
• Sun Care Products (for UV Exposure Areas): Several countries have high exposure to UV rays. In 2024, the population of India was over 1.4 billion, and affordable sun care products and products to correct hyperpigmentation from sun exposure have great potential. However, the growth of such products will be dependent on education by the pharmaceutical companies.
• Sustainability in Packaging: Changes in packaging to reduce environmental impact will lead to new product forms and formats. In 2025, the European Commission introduced new legislation to reduce packaging by 15% in 20 years. Manufacturers of cosmetic products will need to reformulate products to be more sustainable.

Rising consumer awareness will prioritize luxury, and higher prices will be possible through improved product forms and formats. Clinically, such products will be convenient, and will address unmet needs in the market. Companies investing in such products to gain regulatory approval will be rewarded.

Dermatology OTC Medication Market Drivers and Challenges

Factors influencing the global market include the increase in awareness of skin-health issues, the growing trend of self-care, the acceleration of the growth of digital and online markets, and the introduction of new products and amendments in regulations. The increase in the geriatric and the globally mobile populations, as well as the incidence of chronic and reoccurring conditions, provides an ample market potential. The adoption of new and effective products by these populations' further fuels market growth.

The factors responsible for driving this market include:

• Rising Awareness: The global population is becoming more aware of different skin conditions, including acne and other inflammatory conditions, fungal and other infections, hyperpigmentation and other blemishes, and other skin irritations. Concurrent with this growing awareness, the global population is becoming more health-conscious and proactive in seeking preventative care. The American Academy of Dermatology (AAD) and other similar associations are actively engaged in educating the global population regarding skin conditions. The efforts of these associations and the rising incidence of awareness regarding skin conditions are expected to expand the market over the next three to five years.
• Product Innovation: New products integrate multiple functions, simplify use, and enhance convenience. For example, users can find products in multiple forms such as cleansers, creams, patches, gels, sprays. Products target sensitive skin, providing fast actuating and leaving no irritation. 2025 saw a number of large companies launch products targeting the same market with similar formulations (June 2025). The products improve convenience and efficacy, helping consumers shift from using multiple products from other companies.
• Digital Commerce and Teledermatology: The shift to online pharmacies and integrations of teledermatology services improve customers' access to pharmaceutical products and provide educational materials. Online purchases allow companies to engage in post-purchase marketing, potentially creating a subscription. Personalized recommendations and reviews are also valuable. 2025 showed that 20% of all pharmaceutical sales were conducted online. This trend is expected to continue, particularly in unserved areas.
• Increased Regulatory Flexibility and OTC Legislation: Revisions to regulatory frameworks and increased labelling standardization enhance consumer confidence in self-medicating. Simultaneously, modernization encourages investments in improved and innovated packaging. 2025 was active with several regulators updating their policies on nonprescription medications and digital packaging (September 2025).
• Preventive and Sustainable Skincare: Trends observed in 2025 indicate that skincare customers are interested in more preventative approaches and long-term care. There is interest in skincare packaging that is sustainable and reduces its environmental footprint. Packaging that meets the goals set for skincare product packaging shows potential to strengthen brand loyalty. This emphasis on environmental responsibility is expected to create a challenge for manufacturers in strikes a balance between raising product prices and adding fees to cover the costs of more sustainable and/or more effective packaging.

The challenges facing this market include:

• Safety, Misuse and Product Recalls: Manufacturers may face regulatory scrutiny if their products pose a threat to consumer health or if misleading labels contribute to misdiagnoses. Regulatory bodies are likely to increase their scrutiny over the next several years and are likely to require manufacturer oversight of instructions for use of their products.
• Intense Competition and Price Pressure: There is significant competition for consumers in the skincare market, and price sensitivity is expected to continue. Private label skincare and personal care products are expected to continue capturing additional retail space. Manufacturers are expected to focus on Clinical claims in order to achieve and retain market equality and profitability.
• Regulatory Complexity: Global markets require different variations of active ingredients, product claims, product packaging, product registrations, and product advertising. This creates significant barriers to international growth. Additionally, supply chain disruptions can increase cost and delay the launch of a product. Manufacturers attempted to reduce risk in the pharmaceutical and personal care products supply chains by utilizing multiple suppliers and building extra inventory (February 2025). In the coming years, we can expect manufacturers to implement advanced supply chain and forecasting systems and to enhance investment in compliance systems.

The relaxation of global travel and growth in digital health literacy will improve product awareness and purchase convenience. The integration of preventative care and sustainability in product development is expected to improve the product offering in the dermatology OTC medicine market. However, these improvements may be hindered by cheap and potentially unsafe competition. Leading companies will develop sustainable and transparent products and actively distribute their products. Trust and product differentiation will be the key factors for success in the upcoming market cycle.

List of Dermatology OTC Medication Market Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies dermatology otc medication market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the dermatology otc medication market companies profiled in this report include-

• Bayer
• GSK
• Teva
• Johnson & Johnson
• Novartis
• Viatris
• Sun Pharmaceutical
• Aurobindo
• Galderma
• CR SANJIU

Dermatology OTC Medication Market by Segment

The study includes a forecast for the global dermatology otc medication market by type, application, and region.

Dermatology OTC Medication Market by Type [Value ($M) from 2019 to 2035]:

• External Use
• Oral

Dermatology OTC Medication Market by Application [Value ($M) from 2019 to 2035]:

• Hospital
• Drug Store
• Others

Dermatology OTC Medication Market by Region [Value ($M) from 2019 to 2035]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Dermatology OTC Medication Market

The Rules for The Over The Counter (OTC) Dermatology Drug Market Are Changing. Three Main Factors: Tighter control of allowable ingredients, location of drug manufacturing plants, and pace of product development. Based on ongoing trends, between 2025 and 2027, the industry is likely to see the largest regulatory changes of the decade. According to Lucintel, strategic execution will continue to be the key differentiator for companies operating in the market.

• United States: Recent trends in FDA policy have bolstered the production of over-the-counter acne medications and sunscreens. Since 2015, there has been a shift toward the production of single serving packs of OTC medications. In January 2025, the FDA proposed further changes to regulations that would govern over-the-counter pharmaceuticals, requiring all manufacturers to submit their product information electronically. The changes increased the time and resources that companies had to devote to regulatory compliance. As such, companies with greater resources and regulatory know-how are likely to dominate the market.
• China: Chinese manufacturers of OTC drugs and cosmetics continued to expand their product portfolios, particularly in the field of dermatology. Proya Company Limited, a dermatology manufacturer, reported 2024 revenue of approximately 10.4 billion RMB. Trends towards the localization of Chinese regulations, particularly in the field of pharmaceuticals, is expected to increase manufacturing and distribution of dermatological products.
• Germany: Beiersdorf has reported investments in research, digital and production infrastructures to support its growth in the field of dermatology. In February 2025, Beiersdorf released its annual report for 2024 with sales of 9.85 billion euros. Other German OTC manufacturers invest in research and development and acquisition of raw materials to strengthen their technology and supply reliability in the European market.
• India: A similar trend is observed in the Indian pharmaceutical market. Indian companies are expanding their dermatological product lines and strengthening their supply chains to reach pharmacy outlets. Cipla announced its financial results for 2025 with a revenue of 27,548 crore rupees. The investment on its consumer health business is expected to improve affordability and access to dermatological products.
• Japan: Japanese companies focus on research and development of new dermatological products, and develop high-precision products for sensitive skin. Rohto Pharmaceutical reported a 2024 revenue of 270.9 billion yen. Other Japanese manufacturers also follow the same strategy. In the next five years, expect changes in the Japanese OTC dermatology market.

Features of the Global Dermatology OTC Medication Market

• Market Size Estimates: dermatology otc medication market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
• Segmentation Analysis: dermatology otc medication market size by type, application, and region in terms of value ($B).
• Regional Analysis: dermatology otc medication market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the dermatology otc medication market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the dermatology otc medication market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the dermatology otc medication market by type (external use and oral), application (hospital, drug store, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 8 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.1 Macroeconomic Trends and Forecasts
• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global Dermatology OTC Medication Market by Type

• 4.1 Overview
• 4.2 Attractiveness Analysis by Type
• 4.3 External Use : Trends and Forecast 2019 to 2035
• 4.4 Oral : Trends and Forecast 2019 to 2035

5. Global Dermatology OTC Medication Market by Application

• 5.1 Overview
• 5.2 Attractiveness Analysis by Application
• 5.3 Hospital : Trends and Forecast 2019 to 2035
• 5.4 Drug Store : Trends and Forecast 2019 to 2035
• 5.5 Others : Trends and Forecast 2019 to 2035

6. Regional Analysis

• 6.1 Overview
• 6.2 Global Dermatology OTC Medication Market by Region

7. North American Dermatology OTC Medication Market

• 7.1 Overview
• 7.2 North American Dermatology OTC Medication Market by Type
• 7.3 North American Dermatology OTC Medication Market by Application
• 7.4 The United States Dermatology OTC Medication Market
• 7.5 Canadian Dermatology OTC Medication Market
• 7.6 Mexican Dermatology OTC Medication Market

8. European Dermatology OTC Medication Market

• 8.1 Overview
• 8.2 European Dermatology OTC Medication Market by Type
• 8.3 European Dermatology OTC Medication Market by Application
• 8.4 German Dermatology OTC Medication Market
• 8.5 French Dermatology OTC Medication Market
• 8.6 Italian Dermatology OTC Medication Market
• 8.7 Spanish Dermatology OTC Medication Market
• 8.8 The United Kingdom Dermatology OTC Medication Market

9. APAC Dermatology OTC Medication Market

• 9.1 Overview
• 9.2 APAC Dermatology OTC Medication Market by Type
• 9.3 APAC Dermatology OTC Medication Market by Application
• 9.4 Chinese Dermatology OTC Medication Market
• 9.5 Indian Dermatology OTC Medication Market
• 9.6 Japanese Dermatology OTC Medication Market
• 9.7 South Korean Dermatology OTC Medication Market
• 9.8 Indonesian Dermatology OTC Medication Market

10. ROW Dermatology OTC Medication Market

• 10.1 Overview
• 10.2 ROW Dermatology OTC Medication Market by Type
• 10.3 ROW Dermatology OTC Medication Market by Application
• 10.4 Middle Eastern Dermatology OTC Medication Market
• 10.5 South American Dermatology OTC Medication Market
• 10.6 African Dermatology OTC Medication Market

11. Competitor Analysis

• 11.1 Product Portfolio Analysis
• 11.2 Operational Integration
• 11.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

• 12.1 Value Chain Analysis
• 12.2 Growth Opportunity Analysis
  • 12.2.1 Growth Opportunity by Type
  • 12.2.2 Growth Opportunity by Application
• 12.3 Emerging Trends in the Global Dermatology OTC Medication Market
• 12.4 Strategic Analysis
  • 12.4.1 New Product Development
  • 12.4.2 Certification and Licensing
  • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

• 13.1 Competitive Analysis Overview
• 13.2 Bayer
  • Company Overview
  • Dermatology OTC Medication Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.3 GSK
  • Company Overview
  • Dermatology OTC Medication Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.4 Teva
  • Company Overview
  • Dermatology OTC Medication Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.5 Johnson & Johnson
  • Company Overview
  • Dermatology OTC Medication Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.6 Novartis
  • Company Overview
  • Dermatology OTC Medication Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.7 Viatris
  • Company Overview
  • Dermatology OTC Medication Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.8 Sun Pharmaceutical
  • Company Overview
  • Dermatology OTC Medication Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.9 Aurobindo
  • Company Overview
  • Dermatology OTC Medication Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.10 Galderma
  • Company Overview
  • Dermatology OTC Medication Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.11 CR SANJIU
  • Company Overview
  • Dermatology OTC Medication Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

14. Appendix

• 14.1 List of Figures
• 14.2 List of Tables
• 14.3 Research Methodology
• 14.4 Disclaimer
• 14.5 Copyright
• 14.6 Abbreviations and Technical Units
• 14.7 About Us
• 14.8 Contact Us